Orion published Interim Report 1-3/2022 on Thursday, 28 April 2022. The report and related presentation material and a link to webcast is available here.
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
Orion’s virtual Capital Markets Day 2021 was held on 26 May 2021. Presentations and webcast from the event are available here.
Orion Group's Financial Statement documents for 2020 are available here.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|5/10/2022||292,451 Orion Corporation A shares converted into B shares|
|4/29/2022||Composition of the Nomination Committee of Orion Corporation|
|4/28/2022||CORRECTION: Orion Group Interim Report 1–3/2022|
|4/28/2022||Orion Group Interim Report 1–3/2022|
|5/9/2022||The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology|
|5/6/2022||Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain|
|5/3/2022||U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for additional indication of darolutamide|
|4/22/2022||Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.